300705.SZ
Hunan Jiudian Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 10.92
−5.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.0B | 3.1B | 2.9B | 2.7B | 2.3B |
| Cost of Revenue | 855.1M | 841.7M | 784.4M | 615.2M | 517.0M |
| Gross Profit | 2.2B | 2.3B | 2.1B | 2.1B | 1.8B |
| Operating Expenses | |||||
| R&D Expense | 189.5M | 218.4M | 246.0M | 254.1M | 201.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 190.7M | 164.5M | 92.3M | 98.0M | 65.3M |
| Selling & Marketing Expense | 1.3B | 1.3B | 1.2B | 1.3B | 1.2B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.7B | 1.7B | 1.6B | 1.7B | 1.5B |
| Cost and Expenses | 2.6B | 2.6B | 2.4B | 2.3B | 2.0B |
| Operating Income (EBIT) | 453.7M | 537.7M | 575.0M | 394.4M | 291.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 444.3M | 526.4M | 572.2M | 402.2M | 290.2M |
| Income Tax Expense | 45.7M | 56.3M | 59.8M | 33.9M | 20.5M |
| Bottom Line | |||||
| Net Income | 403.8M | 472.8M | 512.4M | 368.3M | 269.7M |
| Earnings from Cont. Ops | 398.5M | 470.0M | 512.4M | 368.3M | 269.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 403.8M | 472.8M | 512.4M | 368.3M | 269.7M |
| Per Share | |||||
| Basic EPS | CN¥0.81 | CN¥0.96 | CN¥1.05 | CN¥0.77 | CN¥0.82 |
| Diluted EPS | CN¥0.81 | CN¥0.95 | CN¥1.04 | CN¥0.73 | CN¥0.82 |
| Revenue Per Share | CN¥5.84 | CN¥6.32 | CN¥6.01 | CN¥5.63 | CN¥7.07 |
| Shares | |||||
| Basic Shares Outstanding | 515.8M | 492.5M | 488.0M | 478.3M | 328.9M |
| Diluted Shares Outstanding | 515.8M | 492.5M | 488.0M | 478.3M | 328.9M |
| Profitability Metrics | |||||
| EBITDA | — | 663.6M | 671.5M | 467.0M | 352.0M |
| D&A | — | 125.9M | 96.5M | 72.7M | 60.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026